Search for Clinical Trial Results

Pyoderma Gangrenosum - 13 Studies Found
Status | Study |
Completed |
Study Name: A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2013-10-15 Interventions: Biological: Xilonix IV |
Terminated |
Study Name: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2014-12-08 Interventions: Drug: gevokizumab |
Terminated |
Study Name: An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2014-12-22 Interventions:
|
Completed |
Study Name: Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2013-06-17 Interventions: Drug: gevokizumab |
Completed |
Study Name: Canakinumab for Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2011-02-17 Interventions: Drug: Canakinumab Monoclonal antibody inhibiting interleukin 1 beta |
Recruiting |
Study Name: An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2017-04-27 Interventions: Biological: Ixekizumab Injection Other Name: Taltz |
Withdrawn |
Study Name: Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2008-08-04 Interventions:
|
Not yet recruiting |
Study Name: Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2017-02-17 Interventions: Drug: APD334 Other Name: Etrasimod |
Recruiting |
Study Name: Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2016-03-28 Interventions: Drug: Secukinumab |
Withdrawn |
Study Name: Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Condition: Pyoderma Gangrenosum Date: 2008-06-02 Interventions: Drug: adalimumab 40 mg weekly adalimumab injection. |